Literature DB >> 2598190

The inhibitory effect of human interferon alpha on the generation of lymphokine-activated killer activity.

Y Tokuda1, N Ebina, S H Golub.   

Abstract

The generation of lymphokine-activated killer (LAK) activity and the proliferative response to human recombinant interleukin-2 (IL-2) were significantly reduced by the presence of human recombinant leukocyte interferon (IFN alpha) in cultures of human peripheral blood mononuclear cells (PBMC). Mature natural killer (NK) cells can be depleted from PBMC with the toxic lysosomotropic agent L-leucine methyl ester. The generation of cytotoxic cells from lymphocytes depleted in leucine methyl ester was also inhibited by indicating that the IFN-alpha effect is not limited to mature cytotoxic NK cells. Depletion of adherent cells from PBMC did not affect the suppression of LAK induction by IFN-alpha. Surface marker analyses of Tac antigen and transferrin receptor (TfR) showed that the presence of IFN alpha throughout the culture period significantly suppressed the typical increase in IL-2-induced Tac- and TfR-positive cells. In contrast, IFN alpha treatment before and after IL-2 culture enhanced LAK cytotoxic activity. Therefore, combinations of these biological response modifiers for clinical use should take into account the dual effect of IFN alpha on key features of the IL-2 response.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2598190     DOI: 10.1007/bf01665006

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  43 in total

1.  The regulatory effect of adherent cells on lymphokine activated killer cells.

Authors:  Y Ibayashi; D S Hoon; S H Golub
Journal:  Cell Immunol       Date:  1987-12       Impact factor: 4.868

2.  Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; S L Schwarz; P J Spiess
Journal:  J Natl Cancer Inst       Date:  1988-11-02       Impact factor: 13.506

3.  Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity.

Authors:  H F Pross; M G Baines; P Rubin; P Shragge; M S Patterson
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

4.  Effect of recombinant alpha interferon on NK and ADCC function in lung cancer patients: results from a phase II trial.

Authors:  P Hokland; M Hokland; B K Olesen; P Ernst
Journal:  J Interferon Res       Date:  1984

5.  Human leukocyte interferon produced by E. coli is biologically active.

Authors:  D V Goeddel; E Yelverton; A Ullrich; H L Heyneker; G Miozzari; W Holmes; P H Seeburg; T Dull; L May; N Stebbing; R Crea; S Maeda; R McCandliss; A Sloma; J M Tabor; M Gross; P C Familletti; S Pestka
Journal:  Nature       Date:  1980-10-02       Impact factor: 49.962

6.  Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin.

Authors:  R Sutherland; D Delia; C Schneider; R Newman; J Kemshead; M Greaves
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

7.  Functional studies on the precursors of human lymphokine-activated killer cells.

Authors:  J D Gray; H Y Shau; S H Golub
Journal:  Cell Immunol       Date:  1985-12       Impact factor: 4.868

8.  Regulatory effect of interferon on T cells in vitro.

Authors:  I Heron; K Berg; K Cantell
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

9.  Role of proliferation in LAK cell development.

Authors:  F J Ramsdell; H Shau; S H Golub
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

10.  Sequential expression of genes involved in human T lymphocyte growth and differentiation.

Authors:  M Krönke; W J Leonard; J M Depper; W C Greene
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

View more
  8 in total

1.  The effects of staphylococcal protein A on human lymphokine-activated killer cell induction.

Authors:  R A Lindemann; K P Singh; H Shau; R K Gupta
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells.

Authors:  A Jewett; B Bonavida
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

3.  Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha.

Authors:  W M Vuist; M J Visseren; M Otsen; K Bos; F A Vyth-Dreese; C G Figdor; C J Melief; A Hekman
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

4.  Immunopathological features of human pulmonary tumors following low-dose interleukin-2.

Authors:  S G Swisher; T M Anderson; D R Wen; M A Stene; A J Cochran; S H Golub; E C Holmes
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine treatment.

Authors:  M Yanase; T Tsukamoto; Y Kumamoto; K Kato; Y Hashimoto
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

6.  Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.

Authors:  G Pichert; L M Jost; W Fierz; R A Stahel
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

7.  Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.

Authors:  A von Rohr; A K Ghosh; N Thatcher; P L Stern
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

8.  In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product.

Authors:  Y Tokuda; Y Ohnishi; K Shimamura; M Iwasawa; M Yoshimura; Y Ueyama; N Tamaoki; T Tajima; T Mitomi
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.